ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc.（SPRY）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
spry · 股价预测 · 10 位分析师（近3月）· FMP · 更新于 2026年6月9日
分析师评级与共识
基于过去 3 个月内 10 位华尔街分析师
Hold
10 位分析师
共识
评级分布
12 个月目标价
High
$26.00
Consensus
$25.50
+183.6% upside
Low
$25.00
Median: $25.5 · Last Close: $8.99
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$25.50
183.6% upside
High Target
$26
189.2%
Low Target
$25
178.1%
Current Price
$8.99
as of today
Based on analyst price targets, the SPRY stock price prediction for the next 12 months ranges from $25 to $26. The consensus SPRY price forecast of $25.50 implies 183.6% upside from the current price of $8.99.
短期股价预测
算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $9.32 | ↑ 3.65% |
1-day model range: $9.24–$9.39. Peak: $9.39 (+3.65%).
长期股价预测
年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $15 | +63.5% |
| 2028 | $20 | +120.5% |
| 2029 | $24 | +162.9% |
| 2030 | $26 | +190.6% |
| 2031 | — | +207.5% |
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · SPRY · Jun 9, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-28 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2025-01-14 | Raymond James | Maintains | Strong Buy→Strong Buy |
| 2025-01-13 | Leerink Partners | Maintains | Outperform→Outperform |
| 2024-10-08 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2024-09-20 | Leerink Partners | Maintains | Outperform→Outperform |
| 2024-09-16 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2024-09-09 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2024-08-13 | Raymond James | Upgrade ↑ | Outperform→Strong Buy |
| 2024-03-11 | Wedbush | Maintains | Outperform→Outperform |
| 2024-03-05 | Leerink Partners | Upgrade ↑ | Market Perform→Outperform |
Wall Street analysts have recently issued updated ratings on ARS Pharmaceuticals, Inc. (SPRY) stock. Of the recent 27 rating actions, 2 were upgrades and 6 were downgrades. 10 analysts currently cover SPRY.
分析师推荐趋势
SPRY analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$149M
↓ 66.5% YoY
Revenue Next Year
$274M
↑ 83.2% YoY
EPS This Year
$-1.75
EPS Next Year
$-0.96
↓ 45.4% YoY
EPS ForecastReported vs Estimated
Analysts forecast SPRY EPS of $-1.75 for the current fiscal year, based on estimates from 4 analysts. The SPRY revenue forecast is $149M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
SPRY 股价预测由两类独立数据源支撑：来自 10 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。SPRY 的共识目标价为 $25.50（+183.6% 上行空间），分析师共识为 Hold。
SPRY 的短期预测（明日）为 $9.32（+3.65%）。 SPRY 对 2027 年的股价预测均值为 $15。 SPRY 对 2030 年的预测区间为 $24–$28。
ARS Pharmaceuticals, Inc. 在 NASDAQ 上市，代码 SPRY。SPRY 在 2027 年的整体展望偏中性/分化，在覆盖分析师中约 40% 对应 Hold 共识。
常见问题
SPRY 预测 · 8 个问题根据 10 位华尔街分析师，SPRY 的 12 个月平均目标价为 $25.50，最高 $26.00、最低 $25.00。若有图表，中位目标价可在上方查看。相对当前价 $8.99，隐含约 +183.6% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.